Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
- Wednesday, October 5, 2022, 7:14
- Business
- Add a comment
CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating…
About the Author
adminasapcorp has written 41532 stories on this site.